AlzeCure Pharma AB ALZCUR

STOCKHOLM, SE / ACCESS Newswire / September 22, 2026 / AB (publ) (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, today announced that the company will participate and present at Swiss Nordic Bio 2026 in Zurich on October 1, a partnering and investor conference connecting Nordic, Swiss and Austrian companies in biotech, medtech and pharma with global investors and industry representatives.At the event, CEO Martin

STOCKHOLM, SE / ACCESS Newswire / September 18, 2026 / AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, today announced that an updated company presentation in English is now available. In the presentation, CEO Martin Jönsson provides an updated view of the company following the recently signed collaboration and outlicensing agreements with US-based Eli Lilly and Denmark-based Quan

STOCKHOLM, SE / ACCESS Newswire / September 8, 2026 / AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6) , which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, today announced that the company will participate in Aktiespararna's Aktiedagen in Stockholm event on September 15. CEO Martin Jönsson will give a corporate presentation and provide an update on the company's recently announced out-licensing and collaboration agreements with Eli

STOCKHOLM, SE / ACCESS Newswire / August 27, 2026 / AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, announced today that it will participate in the Pareto Securities 17th Annual Healthcare Conference on September 2, where CEO Martin Jönsson will give a company presentation and answer questions about the latest developments and AlzeCure's plans for the future.Venue: Hotel At Six, B

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company acquired rights to a preclinical Alzheimer's drug and entered a collaboration for an ion channel program.

STOCKHOLM, SE / ACCESS Newswire / August 18, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company")(STO:ALZCUR)(FRA:AC6) , which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, announced today ...

STOCKHOLM, SE / ACCESS Newswire / August 12, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, announced today ...

STOCKHOLM, SE / ACCESS Newswire / August 3, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) ("AlzeCure" or the "Company") announced in a press release on 1 July 2026 that the Company had entered into an out-licensing and collaboration agreement ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION ...

The lead product on AlzeCure’s platform has already demonstrated positive Phase I results.

STOCKHOLM, SE / ACCESS Newswire / July 1, 2026 / AlzeCure Pharma AB (publ) ("AlzeCure")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, announced today that the company ...

STOCKHOLM, SE / ACCESS Newswire / June 29, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 29 June 2026, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is a summary of the resolutions made. All resolutions ...

If ACD680 were to reach the market, it would deepen Lilly’s Alzheimer’s legacy past anti-amyloid-beta therapy, Kisunla.

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.6% and

AlzeCure Deal Expands Lilly's Neuroscience Pipeline Early

Eli Lilly (LLY) shares were up early Tuesday as the drugmaker entered into a collaboration and licen

STOCKHOLM, SE / ACCESS Newswire / June 9, 2026 / AlzeCure Pharma AB (publ) ("AlzeCure")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, announced today that the company ...

STOCKHOLM, SE / ACCESS Newswire / May 26, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB, reg. no. 559094-8302 (the "Company") are hereby invited to attend the annual general meeting to be held on Monday 29 June ...

STOCKHOLM, SE / ACCESS Newswire / May 13, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that it will ...